Trials / Unknown
UnknownNCT02925702
PRORADIUM: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Radium-223.
Prospective Multi-centre Study of Prognostic Factors in Metastatic Castration-Resitant Prostate Cancer Patients Treated With Radium-223.
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 161 (estimated)
- Sponsor
- Centro Nacional de Investigaciones Oncologicas CARLOS III · Academic / Other
- Sex
- Male
- Age
- 18 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
PRORADIUM is a prospective multicentre observational study in metastatic Castration-Resistant Prostate Cancer (mCRPC), designed to explore prognostic biomarkers in patients undergoing treatment with radium-223.
Detailed description
This study is a prospective biomarker study of patients with mCRPC undergoing treatment with radium-223 as standard of care treatment. The participants will undergo serial pre- and post-therapy blood collection for biomarker analysis as part of the primary objective of the study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Radium 223 55mBq/Kg every 4 weeks intravenously | Radium-223 55kBq/kg infusion IV every 4 weeks |
Timeline
- Start date
- 2016-02-01
- Primary completion
- 2019-01-01
- Completion
- 2020-09-01
- First posted
- 2016-10-06
- Last updated
- 2020-01-27
Locations
63 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02925702. Inclusion in this directory is not an endorsement.